Virtu Financial LLC Purchases Shares of 43,105 Tempest Therapeutics, Inc. (NASDAQ:TPST)

Virtu Financial LLC purchased a new position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 43,105 shares of the company’s stock, valued at approximately $36,000. Virtu Financial LLC owned approximately 0.10% of Tempest Therapeutics as of its most recent filing with the SEC.

Separately, Geode Capital Management LLC boosted its stake in Tempest Therapeutics by 42.7% during the third quarter. Geode Capital Management LLC now owns 220,067 shares of the company’s stock worth $308,000 after acquiring an additional 65,826 shares in the last quarter. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Analysts Set New Price Targets

TPST has been the subject of several research analyst reports. HC Wainwright decreased their price target on shares of Tempest Therapeutics from $47.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, March 28th. Scotiabank reduced their target price on Tempest Therapeutics from $13.00 to $7.00 and set a “sector outperform” rating for the company in a research note on Friday, March 28th.

Tempest Therapeutics Trading Down 3.2 %

NASDAQ TPST opened at $0.71 on Wednesday. The company has a market cap of $31.19 million, a P/E ratio of -0.47 and a beta of -1.83. The company has a fifty day simple moving average of $0.86 and a 200 day simple moving average of $0.97. Tempest Therapeutics, Inc. has a 12-month low of $0.70 and a 12-month high of $6.00.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07). The firm had revenue of $0.49 million for the quarter. Sell-side analysts predict that Tempest Therapeutics, Inc. will post -1.39 EPS for the current year.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.